Pretreatment neutrophil-to-lymphocyte ratio: A predictor of advanced prostate cancer and biochemical recurrence in patients receiving radical prostatectomy

Medicine (United States)

Volumn 94, Issue 41, 2015, Pages

  Zhang, Gui Ming ^a   Zhu, Yao ^a,b   Ma, Xiao Cheng ^c   Qin, Xiao Jian ^a,b   Wan, Fang Ning ^a,b   Dai, Bo ^a,b   Sun, Li Jiang ^c   Ye, Ding Wei ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BODY MASS; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; BLOOD; CYTOLOGY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE; VERY ELDERLY;

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEUTROPHILS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 84944448987     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001473     Document Type: Article

References (22)

1. Zhu Y, Wang HK, Qu YY, et al. Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl. 2015;17:48-57.
2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
3. Choi KW, Hong SW, Chang YG, et al. Inflammation-based score (Glasgow prognostic score) as an independent prognostic factor in colorectal cancer patients. Ann Surg Treat Res. 2014;86:309-313.
4. Moriwaki T, Ishige K, Araki M, et al. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status. Med Oncol. 2014;31:287.
5. Linton A, Pond G, Clarke S, et al. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Clin Genitourin Cancer. 2013;11:423-430.
6. Shafique K, Proctor MJ, McMillan DC, et al. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 2012;15:195-201.
7. Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer. 2012;48:202-208.
8. Cedres S, Torrejon D, Martinez A, et al. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol. 2012;14:864-869.
9. Wei Y, Jiang YZ, Qian WH. Prognostic role of NLR in urinary cancers: a meta-analysis. PLoS One. 2014;9:e92079.
10. Langsenlehner T, Thurner EM, Krenn-Pilko S, et al. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World J Urol. 2015.
11. Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. BJU Int. 2014;114:E11-17.
12. Lorente D, Mateo J, Templeton AJ, et al. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015;26:750-755.
13. Chen C, Lu FC. Department of Disease Control Ministry of Health P R C. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl): 1-36.
14. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol. 2004;4:641-648.
15. Templeton AJ, Pezaro C, Omlin A, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120:3346-3352.
16. Sumbul AT, Sezer A, Abali H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014;46:1531-1535.
17. Gazel E, Tastemur S, Acikgoz O, et al. Importance of neutrophil/lymphocyte ratio in prediction of PSA recurrence after radical prostatectomy. Asian Pac J Cancer Prev. 2015;16:1813-1816.
18. Weitzman SA, Gordon LI. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood. 1990;76:655-663.
19. Kusumanto YH, Dam WA, Hospers GA, et al. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogen-esis. 2003;6:283-287.
20. Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008;454:436-444.
21. Rosenberg SA. Progress in human tumour immunology and immu-notherapy. Nature. 2001;411:380-384.
22. Rashid F, Waraich N, Bhatti I, et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesopha-geal cancer resection. World J Surg Oncol. 2010;8:1.